Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-04
2011-01-04
Davis, Zinna N (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S314000, C514S332000, C514S336000, C514S357000, C546S171000, C546S176000, C546S255000, C546S268100, C546S329000
Reexamination Certificate
active
07863293
ABSTRACT:
The present invention relates to compounds that bind to chemokine receptors, and having the formulawherein each A, X, Y, R1, R2and R3are substituents. The present invention also relates to methods of using such compounds, such as in treating HIV infection and inflammatory conditions such as rheumatoid arthritis. Furthermore, the present invention relates to methods to elevate progenitor and stem cell counts, as well as methods to elevate white blood cell counts, using such compounds.
REFERENCES:
patent: 3205133 (1965-09-01), Biel et al.
patent: 5021409 (1991-06-01), Murrer et al.
patent: 5583131 (1996-12-01), Bridger et al.
patent: 5698546 (1997-12-01), Bridger et al.
patent: 5817807 (1998-10-01), Bridger et al.
patent: 6001826 (1999-12-01), Murrer et al.
patent: 6365583 (2002-04-01), MacFarland et al.
patent: 2002/0147192 (2002-10-01), Bridger et al.
patent: 2003/0028022 (2003-02-01), Bridger et al.
patent: 2003/0220341 (2003-11-01), Bridger et al.
patent: WO-97/09976 (1997-03-01), None
patent: WO-00/02870 (2000-01-01), None
patent: WO-00/56729 (2000-09-01), None
patent: WO-02/22599 (2002-03-01), None
patent: WO-02/22600 (2002-03-01), None
patent: WO-02/34745 (2002-05-01), None
Elderfield et al, Journal of Organic Chemistry (1960), vol. 25, pp. 1576-1583.
Wu et al., Toxicology, 236, pp. 1-6, 2007.
Abi-Younes et al., Circ. Res. (2000) 86:131-138.
Alkhatib et al., Science (1996) 272:1955-1958.
Arai et al., Eur. J. Haematol. (2000) 64:323-332.
Arenberg et al., J. Leukocyte Biol. (1997) 62:554-562.
Aiuti et al., J. Exp. Med. (1997) 185:111-120.
Blaak et al., Proc. Natl. Acad. Sci. (2000) 97:1269-1274.
Blanco et al., Antimicrobial Agents and Chemother. (2000) 44:51-56.
Bleul et al., J. Exp. Med. (1998) 187:753-762.
Bleul et al., Nature (1996) 382:829-833.
Bradstock et al., Leukemia (2000) 14:882-888.
Bridger et al., J. Med. Chem. (1999) 42:3971-3981.
Brinksma et al., Inorganica Chimica Acta (2002) 337:75-82.
Burger et al., Blood (1999) 94:3658-3667.
Carroll et al., Science (1997) 276:273-276.
Cocchi et al., Science (1995) 270:1811-1815.
Connor, J. Virol. (1994) 68:4400-4408.
Deng et al., Nature (1996) 381:661-666.
Donzella et al., Nature Medicine (1998) 4:72-77.
Dragic et al., Nature (1996) 381:667-673.
Egberink et al., J. Virol. (1999) 73:6346-6352.
Eitner et al., Transplantation (1998) 66:1551-1557.
Fedyk et al., J. Leukocyte Biol. (1999) 66:667-673.
Feng et al., Science (1996) 272:872-877.
Gonzalo et al., J. Immunol. (2000) 165:499-50.
Gupta et al., J. Biolog. Chem. (1998) 273(7):4282-4287.
International Search Report for PCT/US04/11328, mailed on Oct. 20, 2004, 2 pages.
Ishii et al., J. Immunol. (1999) 163:3612-3620.
Lataillade et al., Blood (2000) 95:756-768.
Liu et al., Cell (1996) 86:367-377.
Ma et al., Immunity (1999) 10:463-471.
Maekawa et al., Internal Medicine (2000) 39:90-100.
Michael et al., J. Virol. (1998) 72:6040-6047.
Michael et al., Nature Med. (1997) 3:338-340.
Miedema et al., Immune. Rev. (1994) 140:35-72.
Moore et al., J. Invest. Med. (1998) 46:113-120.
Moore et al., Trends Cardiovasc. Med. (1998) 8:51-58.
Murdoch et al., (2000) Blood 95:3032-3043.
Nagasawa et al., Nature (1996) 382:635-638.
Nagase, J. Immunol. (2000) 164:5935-5943.
Nanki et al., J. Immunol. (2000) 164:5010-5014.
Oberlin et al., Nature (1996) 382:833-835.
O'Brien et al., Lancet (1997) 349:1219.
Peled et al., Blood (2000) 95:3289-3296.
Peled et al., Science (1999) 283:845-848.
Ponath, Exp. Opin. Invest. Drugs (1998) 7:1-18.
Rana et al., J. Virol. (1997) 71:3219-3227.
Salcedo et al., Am. J. Pathol. (1999) 154:1125-1135.
Samson et al., Nature (1996) 382:722-725.
Schols et al., Antiviral Research (1997) 35:147-156.
Schols et al., J. Exp. Med. (1997) 186:1383-1388.
Schuitemaker et al., J. Virol. (1992) 66:1354-1360.
Seghal et al., J. Surg. Oncol. (1998) 69:99-104.
Simmons et al., J. Virol. (1996) 70:8355-8360.
Simmons et al., J. Virol. (1988) 72:8453-8457.
Tachibana et al., Nature (1998) 393:591-594.
Tersmette et al., J. Virol. (1988) 62:2026-2032.
Theodorou et al., Lancet (1997) 349:1219-1220.
Viardot et al., Ann. Hematol. (1998) 77:193-197.
Wyatt et al., Science (1998) 280:1884-1888.
Xia et al., J. Neurovirology (1999) 5:32-41.
Yssel et al., Clinical and Experimental Allergy (1998) 28:104-109.
Zhang et al., AIDS Res. Hum. Retroviruses (1997) 13:1357-1366.
Zhang et al., J. Virol. (1998) 72:9307-9312.
Zhang et al., J. Virol. (1999) 73:3443-3448.
Supplementary Partial European Search Report for EP 04759481.7, mailed Feb. 24, 2009, 4 pages.
Baird Ian
Bridger Gary J.
Chen Gang
Harwig Curtis
Kaller Al
Davis Zinna N
Genzyme Corporation
Morrison & Foerster / LLP
LandOfFree
CXCR4 chemokine receptor binding compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CXCR4 chemokine receptor binding compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CXCR4 chemokine receptor binding compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2624662